The BPHL Knockout A-549 Polyclonal Cells product comprises a population of A-549 cells that have been subjected to CRISPR/Cas9-mediated disruption of the human BPHL gene. This polyclonal knockout cell pool, derived by non-clonal selection, provides a heterogeneous loss-of-function model for studying the biological roles of the BPHL-encoded serine hydrolase. Unlike clonal cell lines, polyclonal populations capture a broader spectrum of genetic editing events, which can buffer against clonal artifacts and better represent the complexity of gene knockout in a population context.
The parental A-549 cell line, isolated from a lung adenocarcinoma of a 58-year-old Caucasian male, serves as a widely used type II alveolar epithelial cell model. These adherent epithelial cells are instrumental in respiratory disease research, drug metabolism studies, and cancer biology investigations. Their robust in vitro growth and compatibility with standard transfection and screening protocols make them a reliable chassis for genetic perturbation studies, particularly for examining pulmonary drug handling and metabolic enzyme functions.
BPHL encodes a serine hydrolase that functions primarily as a valacyclovir hydrolase, converting the antiviral prodrug valacyclovir into the active agent acyclovir and the amino acid L-valine. This catalytic activity positions BPHL at a critical juncture in xenobiotic metabolism and the methionine salvage pathway. Although upstream regulatory factors remain poorly defined, the enzyme??s known substrates include valacyclovir and biphenyl compounds, and its downstream products are acyclovir, L-valine, and other ester hydrolysis products. No protein interaction partners have been identified, emphasizing the enzyme??s independent catalytic role in prodrug activation.
In the A-549 lung adenocarcinoma background, disruption of BPHL eliminates the primary route of valacyclovir activation, thereby rendering cells unable to generate acyclovir. This creates a valuable isogenic system to dissect the cellular consequences of impaired prodrug processing, which is particularly relevant to understanding interindividual variability in drug metabolism and susceptibility to valacyclovir toxicity. The knockout model also facilitates investigation of compensatory hydrolase activities and the interplay between drug metabolism and lung cancer cell physiology.
Researchers can employ this polyclonal knockout pool in a variety of experimental contexts, including valacyclovir hydrolysis assays, LC-MS-based quantification of acyclovir and L-valine, cell viability assessments in the presence of valacyclovir, and differential sensitivity to acyclovir. The model is suited for antiviral pharmacokinetic profiling, esterase activity screens, and functional analyses of hydrolase/esterase pathways. It also enables mechanistic studies of the methionine salvage pathway and its intersection with cancer metabolism. For additional technical data or product inquiries, please contact Ascent Research.
